Observational studyThe Journal of infectious diseases2025
Beyond Women's Health: Long-Term Human Papillomavirus-Related Cancer Trends in Norway.
Observational study in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Burden of HPV-associated cancers in Peruvian men: Evidence from national health data.Human vaccines & immunotherapeutics · 2026Article
- Trends in the Incidence of Human Papillomavirus-Related Cancers in Canada and the Netherlands.Cancer control : journal of the Moffitt Cancer CenterObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUnderstanding the total burden of human papillomavirus (HPV)-related cancers is crucial for improving prevention strategies. While organized cervical cancer (CC) screening has been implemented for many years, other HPV-related cancers lacked screening programs. Primary prevention through HPV vaccination has been implemented through national programs, initially for girls and later for boys. To analyze changes in HPV-attributable cancer incidence for both men and women, we used data from the Cancer Registry of Norway (CRN).
methodsThis was an observational population-based study using high-quality data from the CRN. The proportion of cancers at each site attributed to HPV was calculated based on existing literature. We estimated HPV cancer incidence rates from 1990 to 2023 and forecasted incidences until 2038 for cervical squamous cell carcinoma (SCC) and adenocarcinoma, along with other HPV-related SCCs.
resultsAmong men, HPV-attributable cancer incidence was rising, with male oropharyngeal SCC showing the fastest increase (annual percentage change [APC], 4.5; P < .01). Overall, the incidence of HPV-attributable cancers not prevented by screening steadily increased (APC, 2.8; P < .01), surpassing CC incidence and projected to continue rising until 2038. In women, CC remains the most common HPV cancer. However, after an increasing trend since 2004, cervical SCC incidence rates decreased 6% annually from 2018 to 2023 (95% confidence interval [CI], -9.9 to -1.9; P < .01).
conclusionsThe burden of HPV-related cancers beyond CC is increasing in Norway, whereas CC incidence is declining. Addressing the rising total burden of HPV-attributable cancers requires additional preventive measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.